Business Wire

Pharnext Presents Positive Exploratory Phase 2 Data From PXT864 at the 9th Clinical Trials on Alzheimer’s Disease (CTAD) Conference in San Diego, United States

Del

Regulatory News:

Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, presented positive exploratory Phase 2 data for PXT864, a PLEODRUG© being developed for the treatment of Alzheimer’s disease (AD), at the 9th Clinical Trials on Alzheimer’s Disease (CTAD) conference, on December 8-10, 2016 in San Diego (United States).

Data collected during the PLEODIAL© clinical trial suggests that:

  • PXT864 is well tolerated and safe for use in patients with AD: excellent compliance rate above 90%, without serious or unexpected Adverse Events (AE) and no AE led to medical intervention or study treatment discontinuation.
  • PXT864 may slow the progression of cognitive disability in patients with mild AD. The primary endpoint of the study – AD Assessment Scale Cognitive Subscale test (ADAS-Cog-11) – appeared to decline less in the pooled PXT864 dose 1 and 2 groups as compared to historical placebo for mild to moderate patients with AD at week 36.
  • PXT864 may be used concomitantly with low-dose donepezil treatment (5 mg daily): no new safety concern arose when donepezil was administered concomitantly with PXT864 at week 24 and onwards. In addition, concomitant PXT864-donepezil administration pointed towards an improvement or at least a stabilization of ADAS-Cog-11 score at week 36.

These findings show promising efficacy of PXT864 to be further explored in future studies, such as an international multicenter adaptive-design Phase 2 study.

“We believe that these findings bring new evidence of PXT864 safety and efficacy in patients suffering from mild stages of Alzheimer’s disease and this clinical trial has the potential to be a key turning point in the effort to finally provide an efficacious treatment for these patients,” said Daniel Cohen, M.D., Ph.D., Co-Founder and Chief Executive Officer of Pharnext. “These data also further validate our PLEOTHERAPY © research and development approach and we hope to provide novel treatments for many diseases via such synergic drug combinations.”

René Goedkoop, M.D., Chief Medical Officer of Pharnext added, “The data presented provide encouraging evidence for PXT864 as an entirely new approach in the treatment of Alzheimer’s disease. Today there are no treatments capable of altering the progressive course of this terrible disease. We look forward to the continuation of PXT864 clinical development and hope that we can bring an efficacious treatment to people suffering from Alzheimer’s disease and to improve their quality of life.”

PXT864 is a novel rational-design synergic fixed combination of baclofen and acamprosate given orally as a capsule twice a day. PXT864 is thought to restore the disrupted excitatory – inhibitory balance in the brain of patients suffering from neurodegenerative diseases (disrupted by toxic factors such as Aβ oligomeric peptides in Alzheimer’s disease). PXT864’s most advanced target indication is Alzheimer’s disease. Clinical development of PXT864 in other neurodegenerative diseases including Parkinson’s disease and amyotrophic lateral sclerosis (ALS) is also planned.

About Alzheimer’s Disease
Alzheimer’s disease is an irreversible, progressive neurodegenerative dementia. It is characterized by neuronal death in brain structures implicated with memory leading to cognitive deficits such as thinking, memory, personality and behavior disorders. The disease typically develops and worsens gradually over the course of several years and ultimately leads to death. It affects around 25 million people worldwide. Unfortunately, three out of four patients are only diagnosed once the disease is at a severe stage. Alzheimer's disease has no cure and current existing therapies provide only short and modest symptomatic relief.

About PLEODIAL © Trial
The PLEODIAL© trial was an exploratory multicenter single blind Phase 2 study that evaluated 3 doses of PXT864 in 45 patients with mild Alzheimer’s disease who were naïve to anti-dementia treatment: the first two doses were based on the same ratio of baclofen / acamprosate [dose 1 and 2] and the third dose used another ratio [dose 3]. The main objectives were to assess safety, compliance and preliminary efficacy on cognitive and behavioral impairment. The study was designed over a period of 36 weeks: “PLEODIAL-I” for the first 12 weeks followed by “PLEODIAL-II” for the remaining 24 weeks. During PLEODIAL-I, patients received PXT864 during the first 4 weeks (“challenge”) followed by 4 weeks of placebo (“dechallenge”) and then 4 weeks of PXT864 (“re-challenge”). During PLEODIAL-II, patients were invited to continue on PXT864 with the dose they had received during PLEODIAL-I. During the last 12 weeks of the study, physicians were authorized to co-administrate donepezil 5 mg with PXT864. In total, patients were treated with PXT864 for 32 out of 36 weeks in the PLEODIAL-I and II studies. This clinical trial was conducted in 7 French memory centers (CMRR: Centre Mémoire de Ressource et de Recherche) from February 2013 (first patient in) to December 2015 (last patient out).

About Pharnext
Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY©. The Company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG© offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).

For more information, visit www.pharnext.com

PLEODRUG© and PLEOTHERAPY© are registered trademarks by Pharnext

Contact information

Pharnext
Pierre Schwich, +33 (0)1 41 09 22 30
Chief Financial Officer
investors@pharnext.com
or
Investors Relation
NewCap
Julie Coulot, +33 (0)1 44 71 20 40
pharnext@newcap.eu
or
Media Relations (Europe)
Alize RP
Caroline Carmagnol
Margaux Pronost
+33 (0)1 44 54 36 64
pharnext@alizerp.com
or
Media Relations (US)
Russo Partners
Tony Russo, Ph.D.
+1 212-845-4251
tony.russo@russopartnersllc.com
or
Matt Middleman, M.D.
+1 212-845-4272
matt.middleman@russopartnersllc.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

DCS Telecom Selects LeoSat for Innovative Data Solution13.12.2017 10:03Pressemelding

LeoSat Enterprises, which is launching a constellation of up to 108 low-earth-orbit communications satellites, has entered into an agreement with DCS Telecom, a leading telecoms provider of satellite and networking solutions in the Middle East, Africa and Asia. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171213005443/en/ DCS Telecom Selects LeoSat for Innovative Data Solution (Photo: Business Wire) DCS Telecom will use LeoSat to upgrade its existing satellite solutions, giving customers access to a unique low-latency network which is expected to revolutionize data connectivity. LeoSat’s system of low earth orbit communications satellites can achieve lower latency and stronger end-to-end security compared to traditional satellite and terrestrial solutions used today. This is achieved through an adv

Andersen Global Expands Presence in Germany with Addition of Thierhoff Müller & Partner13.12.2017 08:01Pressemelding

Andersen Global is proud to announce an expanded presence in Germany as Thierhoff Müller & Partner, a tax and legal firm with offices in Leipzig and Frankfurt, combines its practice with Andersen Tax & Legal in Germany. Through its German member firms, Andersen Tax & Legal and Alegis Steuerberatungsgesellschaft mbH, Andersen Global now has more than 65 professionals focused on providing tax and legal services and business advice across five locations in Germany, including Cologne, Dusseldorf, and Merzig. “Thierhoff Müller is highly regarded in complex restructuring matters. Together with our existing legal and tax practice, we will be able to increase our service offerings for our clients,” said Stefan Kraus, Managing Partner of Andersen Tax & Legal in Germany. “We are dedicated to providing outstanding service and are adding additional competencies in tax and legal such as corporate r

Aprecia Pharmaceuticals and Cycle Pharmaceuticals Partner to Develop 3D-Printed Orphan Drugs13.12.2017 08:00Pressemelding

Aprecia Pharmaceuticals, LLC (“Aprecia”), The 3DP Pharmaceutical Company, and Cycle Pharmaceuticals, Ltd. (“Cycle”) today announced they have signed a partnership agreement to develop and commercialize orphan drugs using three-dimensionally printed (“3DP”) technology. The planned products will deliver quality-of-life improvements versus existing, approved orphan drugs, and will achieve this by utilizing Aprecia’s proprietary 3DP ZipDose® Technology platform. ZipDose® is the only three-dimensional printing technology used in a pharmaceutical drug product approved by the U.S. Food and Drug Administration. Antonio Benedetti, CEO of Cycle commented: “Many rare disease patients do not have a treatment option at all. For those rare diseases where there is an approved pharmaceutical treatment, patients continue to be burdened by sub-optimal drug formulations. Aprecia’s

Group Vivendi Africa Deploys Netcracker OSS to Enhance Service Management as it Expands Across the Continent12.12.2017 16:07Pressemelding

Netcracker Technology announced today that its OSS suite was selected and deployed to support the long-term growth strategy of Group Vivendi Africa (GVA). GVA is a newly formed affiliate of the French-based multinational conglomerate Vivendi with the goal to deploy and operate a fiber network across Africa. Netcracker's OSS will be used as a consolidated solution to identify service availability across GVA's operating countries and then fulfill and provision those services to customers. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005937/en/ Netcracker's highly productized, out-of-the-box applications enabled the OSS suite to be deployed in seven months, meeting GVA's demand to leverage an integrated service fulfillment and inventory solution that could satisfy its long-term growth expectations, as well as s

Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program12.12.2017 15:23Pressemelding

Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today released its latest Scientific Update for Smoke-Free Products, a regular publication on its research efforts to develop and assess a range of smoke-free alternatives to cigarettes. The latest issue of the Scientific Update can be found at this link. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005891/en/ Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program (Photo: Business Wire) This issue of the Scientific Update provides a closer look at some of the principles and practices on which PMI’s scientific assessment program is built. Director Medical Affairs Dr. Patrick Picavet describes specific examples from PMI’s clinical program that highlight the company’s

Murex to Offer MX.3 Risk, Trading and Post-Trade Solutions on the AWS Cloud12.12.2017 14:00Pressemelding

Murex, an industry leader in trading, risk management and processing solutions for capital markets, announced they will run their MX.3 technology platform on Amazon Web Services, Inc. (AWS). With the acceleration of cloud adoption in capital markets, Murex and AWS agreed to collaborate to help clients migrate their Murex application workloads to the AWS Cloud. Murex clients are looking to consolidate more and more of their capital markets activity on the MX.3 platform and this means their need for infrastructure is increasing. New regulatory requirements are also driving financial organizations to use cloud to scale up their computing capacity. Murex is collaborating with AWS to meet the demand from clients to support deployment of the Murex offering on the AWS Cloud. Murex is working on the validation of a range of deployment scenarios, from using AWS Cloud for bursting grid

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom